<DOC>
	<DOCNO>NCT00179738</DOCNO>
	<brief_summary>Subjects qualify receive single agent oral lenalidomide daily day 1-21 every 28 day cycle . Subjects continue study document disease progression</brief_summary>
	<brief_title>A Multicenter , Single-Arm , Open-Label , Study Evaluate Safety Efficacy Single-Agent Lenalidomide ( Revlimid , CC-5013 ) Subjects With Androgen Independent Prostate Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent form . 2 . Age &gt; = 18 year time signing informed consent form . 3 . Able adhere study visit schedule protocol requirement . 4 . Must histologic diagnosis adenocarcinoma prostate . 5 . Must surgically medically castrate . If method medical castration , subject must serum testosterone level &lt; 50 ng/dl . The subject maintain treatment LH RH antagonists agonist . 6 . Must prostate cancer unresponsive refractory androgen blockade demonstrate rise PSA . Rising PSA define least 2 consecutive rise PSA document reference value ( measure 1 ) . The first rise PSA ( measure 2 ) must take least 7 day reference value . A third confirmatory PSA require , must obtain least seven day second measure . If great measure 2 , fourth PSA require must great measure 2 . Absolute value PSA &gt; = 5 ng/ml last confirmatory assessment . 7 . Prior treatment antiandrogens flutamide , hormonal agent estrogen , corticosteroid , ketoconazole must stop least 28 day prior treatment . In case nilandron bicalutamide , treatment agent must stop least 42 day prior treatment . Following completion antiandrogen withdrawal period , either : One post withdrawal PSA value must higher last prewithdrawal PSA value , If subject PSA value decrease follow antiandrogen withdrawal period two increase PSA value must document postwithdrawal nadir . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 ( Appendix II : ECOG Performance Status Scale ) . 1 . Metastatic prostate cancer 2 . Any following laboratory abnormality : 1 . Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 ( 1.5 x 109/L ) 2 . Platelet count &lt; 100,000 cells/mm3 ( 100 x 109/L ) 3 . Serum creatinine &gt; 2.5 mg/dL ( 221 mmol/L ) 4 . Serum SGOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) 5 . Serum total bilirubin &gt; 2.0 mg/dL ( 34 mmol/L ) 3 . Any condition , include presence laboratory abnormality , place subject unacceptable risk participate study confound ability interpret data study . 4 . Prior history malignancy AIPC ( except basal cell squamous cell carcinoma skin ) unless subject free disease &gt; = 1 year . 5 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 6 . Prior &gt; = grade 3 allergic reaction/hypersensitivity thalidomide . 7 . Prior &gt; = grade 3 rash desquamating ( blister ) rash take thalidomide . 8 . Prior use lenalidomide . 9 . Prior use chemotherapy androgen independent prostate cancer . 10 . Use standard/experimental anticancer drug therapy within 28 day initiation study drug therapy except LHRH agonists/antagonists . 11 . Known active Hepatitis C .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Androgen Independent Prostate Cancer</keyword>
</DOC>